Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2014; 20(44): 16398-16408
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16398
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16398
Recent applications of chemosensitivity tests for colorectal cancer treatment
Yong Sik Yoon, Jin Cheon Kim, Department of Surgery, University of Ulsan College of Medicine, Seoul 138-736, South Korea
Yong Sik Yoon, Jin Cheon Kim, Institute of Innovative Cancer Research and Asan Institute for Life Sciences, Asan Medical Center, Seoul 138-736, South Korea
Author contributions: Yoon YS designed and wrote the paper; Kim JC designed, wrote and revised the paper.
Supported by Grants from Asan Institute for Life Sciences, No. 2014-69; the National Research Foundation, No. NRF-2013R1A2A1A03070986; Ministry of Science, ICT, and Future Planning, the Korea Health 21 RD Project, No. HI06C0868 and No. HI13C1750; and the Center for Development and Commercialization of Anti-Cancer Therapeutics, No. HI10C2014, Ministry of Health and Welfare, South Korea
Correspondence to: Jin Cheon Kim, MD, PhD, Department of Surgery, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul 138-736, South Korea. jckim@amc.seoul.kr
Telephone: +82-2-30103499 Fax: +82-2-4749027
Received: May 15, 2014
Revised: July 8, 2014
Accepted: August 13, 2014
Published online: November 28, 2014
Processing time: 200 Days and 17.9 Hours
Revised: July 8, 2014
Accepted: August 13, 2014
Published online: November 28, 2014
Processing time: 200 Days and 17.9 Hours
Core Tip
Core tip: This review summarizes currently available predictive and prognostic chemosensitivity tests and biomarkers in terms of cell culture, protein, and gene. Cell culture-based chemosensitivity tests are used widely in clinical practice because of their short assay period, technical simplicity, and the requirement of small amount of specimen. Among protein- and gene-based chemosensitivity assays, assessment of KRAS mutation status predicts the response to epidermal growth factor receptor-targeted therapy in colorectal cancer patients.